drug
BH-30236
Phase 1updated 3mo agoby BlossomHill Therapeutics Inc
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying BH-30236
News(3)
- BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOsBlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…biospace · 8d ago
- BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challengerBlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.fiercebiotech · 15d ago
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…fiercebiotech · 1mo ago
Data sources
last refreshed 23m ago
Found something off?
comments(0)
5-min edit window · permanent after that